We describe the isolation of a novel protein from the conditioned medium of human articular cartilage chondrocytes in primary culture. This 39-kDa protein has the N-terminal sequence YKL, which we have termed YKL-39. The 1434-nucleotide sequence of the YKL-39 cDNA predicts a 385-residue initial translation product and a 364-residue mature YKL-39. The amino acid sequence of YKL-39 is most closely related to YKL-40, followed by macrophage chitotriosidase, oviductal glycoprotein, and macrophage YM-1. All five proteins share significant sequence identity with bacterial chitinases and have the probable structure of an (αβ)8 barrel. YKL-39 lacks the active site glutamate, which is essential for the activity of chitinases, and as expected has no chitinase activity. The highest level of YKL-39 mRNA expression is seen in chondrocytes, followed by synoviocytes, lung, and heart. YKL-39 accounts for 4% of the protein in chondrocyte-conditioned medium, prostromelysin accounts for 17%, and YKL-40 accounts for 33%. In contrast to YKL-40, YKL-39 is not a glycoprotein and does not bind to heparin.

In this study we report the discovery of a new member of the mammalian protein family related in sequence to bacterial chitinases. This protein family has an (αβ)8 barrel structure (1, 2) and includes a protein secreted from human macrophages that does have chitinase activity, which is termed chitotriosidase (3), and three proteins with no presently known enzymatic activity, YKL-40 (4), YM-1 (GenBank1/EBI accession number M94584), and oviductal glycoprotein (6). Because the new member of this family, which we have termed YKL-39, is more closely related in size and sequence to YKL-40 than to other members of this family, it is useful to summarize research on YKL-40 as a background for the present investigation.

YKL-40 is a 40-kDa glycoprotein that was first discovered as a heparin-binding protein secreted from bovine breast tissue during the massive tissue involution that follows the cessation of lactation (7). YKL-40 was subsequently discovered as a heparin-binding protein in the conditioned medium of human synovocytes (8), chondrocytes (4, 9), and the MG-63 osteosarcoma cell line (10). YKL-40 has also been discovered as a heparin-binding protein expressed by porcine vascular smooth muscle cells undergoing a differentiation transition (11) and as a protein expressed selectively by murine mammary tumors initiated by neu/eras oncogenes (12). The present studies were initiated to further examine the expression of YKL-40 by human articular cartilage chondrocytes in culture. In the course of these studies YKL-39 was found as a protein that copurified with YKL-40.

We report here the discovery, purification, characterization, and sequence of human YKL-39.

MATERIALS AND METHODS

Isolation and Culture of Chondrocytes and Synovocytes—Chondrocytes and synovocytes were obtained from Martin Lotz, director of the University of California, San Diego osteoarthritis cell culture facility and were isolated and cultured essentially as described (13). Cartilage from the femoral condyles and tibial plateaus of the knee joints was obtained at autopsy from donors without known history of joint disease or from healthy organ donors from the University of California, San Diego tissue bank. Cartilage slices were cut into pieces (2–3 mm3), washed with DMEM, and treated for 15 min with trypsin (10% v/v) in a 37 °C water bath. The tissues were transferred to DMEM containing 5% fetal calf serum, penicillin-streptomycin-Fungizone, and 2 mg/ml dextran-coated collagenase type IV (Sigma) and digested overnight on a shaker until the tissue fragments were dissolved. The cells were washed three times with DMEM and cultured in T175 flasks containing 30 ml of DMEM plus 10% fetal calf serum until confluent. All experiments reported here used chondrocytes in primary culture or at passage 1 following a 1:3 subculture. To harvest conditioned culture medium, chondrocyte cultures were grown to confluence in T175 flasks, washed twice with 30 ml of phosphate-buffered saline, and cultured in 30 ml of serum-free DMEM for 1 week.

Synovial tissues were obtained from knee joints and washed with DMEM, minced, and treated with trypsin (10% v/v) for 15 min in a 37 °C water bath. The tissue fragments were then transferred to DMEM containing 5% fetal calf serum, penicillin-streptomycin-Fungizone, and 2 mg/ml dextran-coated collagenase type IV (Sigma) and digested on a shaker until dissolution of the fragments (about 3 h). The cells were washed three times with DMEM and cultured in T175 flasks. After 24 h nonadherent cells were removed, and the adherent synovial cells were further cultured until confluent and then harvested for RNA isolation.

Purification of YKL-39—To fractionate conditioned medium proteins by size (see Fig. 1), 200 ml of medium obtained after 1 week of culture in serum-free conditions was concentrated to 5 ml by ultrafiltration using a 10-kDa MWCO membrane and applied to a 2 × 150-cm Sephacryl S-300 HR column equilibrated with 150 mM NH4HCO3 at room temperature. To remove YKL-40 and other heparin-binding proteins, 600 ml of conditioned medium was passed through a 2 × 15-cm heparin-Sepharose CL-6B column initially equilibrated with 20 mM sodium phosphate buffer, pH 7.4. The unbound proteins were concentrated to 5 ml by ultrafiltration and then applied to a 2 × 150-cm Sephacryl S-300 HR column equilibrated with 150 mM NH4HCO3 at room temperature (see Fig. 2).

SDS-PAGE—SDS-polyacrylamide gel electrophoresis was performed under reducing conditions using 4–20% gradient gels (Novex, San Diego, CA) and stained with Coomassie Brilliant Blue or with the periodic acid-Schiff reaction (glycoprotein detection kit, Sigma). Conditioned medium was obtained from primary chondrocytes cultured in the ab-
Isolation and Sequence of Human Chondrocyte YKL-39

sence of serum for 7 days and was dialyzed against milli Q water before concentration for electrophoresis (see Fig. 1, inset, lane 2).

N-Terminal Protein Sequence Analysis—Purified proteins were transferred to polyvinylidene difluoride membranes using a ProSpin device (Applied Biosystems, Foster City, CA) and sequenced using a Perkin-Elmer/Applied Biosystems Division model 494 sequencer equipped with online high performance liquid chromatography. Sequencing of the YKL-39 cDNA—As explained under “Results,” done 118899 isolated by the Washington University-Merk EST Project from a human lung cDNA library proved to be a cDNA clone of YKL-39. We purchased this clone from Genome Systems, Inc. (St. Louis, MO). Small and Xhol digestion of this clone showed that it contains a 1.5-kilobase insert. We sequenced the 5’ and 3’ ends of the insert DNA using a T7 primer and a M13 reverse primer for the PhBlueScript SK(−) phagemid and a version 2.0 DNA sequencing kit (U. S. Biochemical Corp.). Synthetic primers were synthesized from the DNA sequences and used to extend the sequence in increments until the sequence of both strands was determined.

Northern Blot Analysis—Total RNA was isolated from chondrocytes, synoviocytes, MG-63 osteosarcoma cells, normal dermal fibroblasts, and Hep G2 liver cells with an RNA STAT-60™ kit (Tel-Test B, Inc., Friendswood, TX). Thirty μg of total RNA from each cell line was fractionated on a 1% formaldehyde-agarose gel in 4-morpholinepropane-sulfonic acid buffer and transferred onto a Hybond-N membrane (Amersham Corp.). A multiple tissue Northern blot containing total RNA from human heart, brain, kidney, liver, lung, pancreas, and spleen was purchased from BioChain Institute, Inc. (San Leandro, CA). Following prehybridization for 3 h in 50% formamide, 5 × SSC, 5 × Denhardt’s solution, and 100 μg/ml denatured salmon sperm DNA at 42 °C, blots were hybridized with random primed 32P-labeled cDNA probes for 16–20 h under identical conditions. Filters were washed three times for 1 h each with 0.1 × SSC containing 0.1% SDS at 65 °C and then exposed to x-ray film. The blots were first hybridized with the EcoRI fragment of done 118809 (nucleotides 388–1256, see Fig. 4) and after exposure to x-ray film were then stripped by boiling in H2O containing 0.5% SDS and rehybridized with cDNA probes for YKL-40 (nucleotides 135–916, see Ref. 4) and glyceraldehyde-3-phosphate dehydrogenase. Determination of Chitinase Activity—The chitinase activity of YKL-39 was tested with the fluorogenic substrates 4-methylumbelliferyl β-N,N′-diacyctylchitobiose and 4-methylumbelliferyl β-o-N,N′-triacetyltetrchiotriose (Sigma), and the N,N′-dinitrophenyl-β-o-N,N′-triacetyltetrchiotriose (Sigma), as described by Renkema et al. (14). Chitinase from Serratia marcescens (Sigma) was used as a positive control.

RESULTS

Purification of Cousin—To harvest proteins secreted from chondrocytes, primary cultures of human articular cartilage chondrocytes were grown to confluence in media containing 10% fetal calf serum and then switched to serum-free medium. After 1 week of culture, conditioned medium was concentrated by ultrafiltration and fractionated by molecular weight using a Sephacryl S-300 HR column. Proteins were electrophoresed on a 4–20% gradient polyacrylamide gel electrophoresis of fractions from the Sephacryl S-300 HR column. Proteins were electrophoresed on a 4–20% gradient gel and stained with Coomasie Brilliant Blue. Lane 1, molecular mass standards; lane 2, 0.5 ml of chondrocyte-conditioned medium; lane 3, 10 μg of fraction 70; lane 4, 10 μg of fraction 79; lane 5, 10 μg of fraction 83.

Several experiments were carried out to ascertain the cause of the asymmetry in the YKL-40 peak centered at fraction 79 in Fig. 1. When the level of YKL-40 was determined by radioimmunoassay (9), there was a good correlation between A220 and immunoreactivity for fractions 77–80 but less immunoreactivity than expected based on absorbance for fractions 81–84 (data not shown). This result indicated the possible presence of an A220-absorbing protein constituent not recognized by the radioimmunoassay for YKL-40. SDS-PAGE of fraction 83 revealed a doublet at 39–40 kDa (Fig. 1, inset). N-terminal protein sequencing of fraction 83 revealed the apparent presence of two sequences, and therefore two proteins, each in approximately equimolar amounts. One sequence is that of YKL-40 (YLKVXYTTSWSQYR−) and the other is very similar to YKL-40 (YLKVLYETFNWSDR−).

To further evaluate the possible existence of a putative YKL-40-related protein, another portion of the serum-free conditioned medium whose fractionation is shown in Fig. 1 was separated by SDS-PAGE (Fig. 1, inset) and transferred to a polyvinylidene difluoride membrane. Subsequent N-terminal protein sequencing of the intense protein band centered at 40 kDa revealed a mixture of two sequences, the major (90%) of which is identical to YKL-40 and the minor (10%) of which is identical to the putative YKL-40-related protein. Interestingly, the N-terminal sequencing of YKL-40 purified from conditioned medium by heparin affinity chromatography, our customary procedure for purification of the protein (9), yielded only the expected sequence of YKL-40 with no trace of the putative YKL-40-related protein.

To see whether the putative YKL-40-related protein might be among the conditioned medium proteins that did not bind to the heparin column, the unbound protein fraction was concentrated by ultrafiltration and fractionated by molecular weight.
notaglycoprotein, whereas, as previous studies have shown (4, 5), gel filtration for carbohydrates showed that the YKL-40-related protein is a mixture of human prostromelysin and bovine fraction 76. N-terminal protein sequencing of fraction 76 revealed it to be a mixture of human prostromelysin and bovine fraction 76. N-terminal protein sequencing of fraction 76 revealed the presence of a single sequence, YKLVXYFTNWSQDRQEGFKFTPEGKFTPEN1, the sequence predicted for the YKL-40-related protein, with no trace of the YKL-40 sequence itself. SDS gel electrophoresis revealed this protein to be 39 kDa in apparent mass and therefore slightly smaller than YKL-40 (Fig. 3a), and staining of the gel for carbohydrate showed that the YKL-40-related protein is not a glycoprotein, whereas, as previous studies have shown (4, 7), YKL-40 itself is (Fig. 3b). Since YKL-40 and the YKL-40-related protein have the same N-terminal sequence YKL but different apparent mass, we have given the YKL-40-related protein the provisional name YKL-39 to denote its 39-kDa apparent mass and so distinguish it from the 40-kDa YKL-40. The other major protein component seen in the chromatogram shown in Fig. 2 emerges in an asymmetric peak centered at effluent fraction 91. N-terminal sequencing of the mature YKL-39 protein containing a 21-residue transmembrane signal peptide revealed it to be a mixture of human prostromelysin and bovine albumin.

Based on the recovery of A220 absorbance, a direct measure of total protein, we calculate from the data in Figs. 1 and 2 that 10 confluent T175 flasks of articular cartilage chondrocytes accumulate 18 mg of total protein (assuming a 1 mg/ml protein concentration has an A220 = 10.0) into conditioned medium after 1 week of culture in serum-free conditions. Of this total, YKL-40 accounts for 6 mg (33% of total protein) and YKL-39 accounts for 0.75 mg (4%). The five fractions in Fig. 1 that contain almost all of the prostromelysin (fractions 69-73; based on SDS-PAGE) account for 3 mg of the conditioned medium protein (17%). Because these fractions are contaminated with albumin, the actual amount of prostromelysin in conditioned medium must be somewhat lower.

Determining the cDNA Sequence of YKL-39—Before initiating efforts to clone YKL-39 we investigated the possibility that clones for YKL-39 may have already been partially sequenced as part of the Washington University-Merck EST Project. One approach was to design a predicted cDNA sequence from the N-terminal 25-residue sequence of YKL-39 using where possible the preferred codon usage in humans. When we used this to screen the EST data base with the Blast N program (15), only one sequence gave a significant match, clone 257753 (GenBank™/EBI accession number N40107). The other approach was to use the known cDNA sequence of YKL-40 itself to identify sequences closely related to, but not identical with, YKL-40. This approach yielded an additional clone, clone 118809 (GenBank™/EBI accession number T91693). The partial sequences for clones 257753 and 118809 that were available in the EST data base indicated a region of overlap identity, and we therefore concluded that they were clones of the same gene. We then obtained clone 118809 and determined its complete cDNA sequence.

Fig. 4 shows the complete nucleotide sequence of clone 118809 and the deduced amino acid sequence of YKL-39. The coding region of YKL-39 is terminated by a TGA triplet at nucleotide 1191 and is followed by 242 nucleotides of 3'-untranslated region with a potential polyadenylation signal (AATAAA) at nucleotides 1391-1396. The ATG, found at nucleotides 36-38, was considered to be the initiation codon according to the rules for translation initiation described previously (16). The open reading frame codes for a 385-residue long protein containing a 21-residue transmembrane signal peptide with a potential signal peptidase cleavage site at amino acid residue 21 (17). The predicted protein, after removal of the signal peptide, has a length of 364 amino acids and a calculated molecular mass of 40,825 Da. The predicted N-terminal sequence of YKL-39 is identical to the N-terminal 25-residue sequence determined by protein sequencing of the purified protein.

The putative NXS site of N-glycosylation in YKL-40, asparagine residue 60 and serine residue 62 (4), is not found in YKL-39. There is a single potential recognition site for N-glycosylation in YKL-39, the NWS sequence at residues 30 to 32. This site does not appear to be a functional site of N-glycosylation in YKL-39 secreted from chondrocytes, however, since no carbohydrate could be detected in purified YKL-39 (Fig. 3b) and N-terminal sequencing of the mature YKL-39 revealed the expected repetitive yield of asparagine at residue 9. Although the predicted number of amino acid residues in the mature form of YKL-39 is slightly larger than for YKL-40 (364 versus 362 residues), the presence of carbohydrate in YKL-40 but not in YKL-39 is probably sufficient to account for the fact that YKL-40 appears to be slightly larger than YKL-39 based
onitselutionpositionfromSephacrylS-300HR(Fig.1)andonitsapparentSDS-PAGEmolecularweight(Fig.3).

Tissue and Cell-type Specificity of YKL-39 mRNA Expression—
Five cell cultures were tested for the production of YKL-39 by Northern blot. The 32P-labeled cDNA probe for YKL-39 hybridized with a single 1.5-kilobase band in the chondrocyte and synoviocyte RNA samples (Fig. 5a). This size is in good agreement with the 1434-base pair size of clone 118809.

No YKL-39 mRNA could be detected in RNA from normal human fibroblasts, the HEP G2 human liver cell line, and the MG-63 human osteoblastic osteosarcoma cell line. As expected (4, 10), reprobe of this membrane demonstrated high levels of YKL-40 mRNA in chondrocytes and MG-63 cells, lower levels in synoviocytes, and undetectable levels in HEP G2 and fibroblasts (data not shown). The lack of YKL-39 mRNA expression by MG-63 cells is in agreement with the fact that the previously reported N-terminal protein sequencing of the 40-kDa protein band seen in SDS-PAGE of MG63 conditioned media identified the sequence of YKL-40 but failed to detect evidence of the sequence of YKL-39 (10).

It is possible that culture under the serum-free conditions that are needed for protein isolation from conditioned medium could significantly alter the quantitative pattern of secreted protein expression. To evaluate the possible effect of serum-free conditions on YKL-39 expression, confluent primary chondrocytes were cultured for 1 week in serum-free medium or in medium containing 10% fetal calf serum, and the level of YKL-39 was determined by Northern blot. The YKL-39 levels in the serum-free and serum-containing cultures proved to be identical (data not shown). We could also detect no effect of serum-free conditions on the level of YKL-40 mRNA or on the medium levels of YKL-40 antigen.

Seven tissues from adult humans were examined for the presence of YKL-39 mRNA (Fig. 6). No YKL-39 mRNA could be detected in RNA from normal human fibroblasts, the HEP G2 human liver cell line, and the MG-63 human osteoblastic osteosarcoma cell line. As expected (4, 10), reprobe of this membrane demonstrated high levels of YKL-40 mRNA in chondrocytes and MG-63 cells, lower levels in synoviocytes, and undetectable levels in HEP G2 and fibroblasts (data not shown). The lack of YKL-39 mRNA expression by MG-63 cells is in agreement with the fact that the previously reported N-terminal protein sequencing of the 40-kDa protein band seen in SDS-PAGE of MG63 conditioned media identified the sequence of YKL-40 but failed to detect evidence of the sequence of YKL-39 (10).

Protein expression. To evaluate the possible effect of serum-free conditions on YKL-39 expression, confluent primary chondrocytes were cultured for 1 week in serum-free medium or in medium containing 10% fetal calf serum, and the level of YKL-39 was determined by Northern blot. The YKL-39 levels in the serum-free and serum-containing cultures proved to be identical (data not shown). We could also detect no effect of serum-free conditions on the level of YKL-40 mRNA or on the medium levels of YKL-40 antigen.

Seven tissues from adult humans were examined for the presence of YKL-39 mRNA (Fig. 5b). YKL-39 mRNA is expressed strongly in lung and is detectable in heart. No YKL-39 mRNA could be detected in brain, spleen, pancreas, or liver. A reprobe of this membrane failed to detect YKL-40 mRNA in any of these tissues. Further evidence on the tissue distribution of YKL-39 mRNA expression is provided by the frequency with which YKL-39 cDNA clones have been identified by the Washington University-Merck EST Project. Two different clones have been obtained from a human lung cDNA library (GenBank™/EBI accession numbers T91693 and T66009), one clone has been obtained from each of two infant brain libraries (GenBank™/EBI accession numbers H10721 and H10989), and one has been obtained from a placenta library (GenBank™/EBI accession number N40107). This evidence suggests that YKL-39 may also be expressed in developing brain and in placenta.
Comparison of YKL-39 to Related Mammalian Proteins—Pairwise comparison of YKL-39 with the four previously identified mammalian members of the protein family related in sequence to bacterial chitinases using the ALIGN program (Protein Identification Resource) shows that YKL-39 is most closely related to human YKL-40 (4) followed by human chitotriosidase (3), human oviductal glycoprotein (6), and murine YM-1 (GenBank™/EBI accession number M94584). The regions of sequence identity encompass all of YKL-39, YKL-40, and YM-1 and the N-terminal domains of chitotriosidase and of oviductal glycoprotein. The C-terminal domain of chitotriosidase is related to the C-terminal domain of nematode and insect chitinases (3) and has no counterpart in YKL-40, YKL-39, or YM-1. The C-terminal domain of oviductal glycoprotein is thought to be a region of extensive protein glycosylation (6).

The amino acid sequence of YKL-39 is compared to the two proteins which are most closely related to it in sequence, YKL-40 and chitotriosidase, in Fig. 6. As can be seen, there is extensive sequence identity among all three human proteins, particularly in the regions that are thought to be involved in substrate binding in the bacterial chitinases (18, 19) (Fig. 6, shaded residues). It is of interest to note that the glutamate residue which is known from mutagenesis studies to be essential for the activity of bacterial chitinases (20) is found in chitotriosidase (Fig. 6, glutamate 139) but not in YKL-39, YKL-40, YM-1, or oviductal glycoprotein. This observation is consistent with the fact that chitotriosidase is a glycosidic bound hydrolase, while no enzymatic activity has yet been reported for YKL-40, YM-1, or oviductal glycoprotein. Although we have not carried out extensive tests of the possible enzymatic activities of YKL-39, we did examine its possible chitinase activity (see "Materials and Methods"). YKL-39 was not active in any of the four assays tested (data not shown).

The high degree of sequence identity between YKL-40 and YKL-39, which includes continuous stretches of identity up to 10 residues in length, suggests that antibodies against one protein could cross-react with the other. We therefore tested the possible cross-reactivity of YKL-39 on the radioimmunooassay that we developed for measurement of human YKL-40 in serum and tissues (9). No cross-reactivity was observed, which indicates that the dominant epitope recognized by the antisera used for the YKL-40 assay does not recognize YKL-39. It should be noted, however, that this result does not rule out the presence of minor cross-reacting antibodies in this antiserum.

Recent investigations have assigned bacterial chitinases and the related mammalian proteins to a gene family termed family 18 of the glycosylhydrolases (1). Based on the crystallographic structure of one member of this family, it has been further suggested that all members of this gene family have the tertiary structure of an (αβ)8 barrel (also called a TIM barrel) (2). TIM barrels are the most common architecture of enzymes and are found in 10% of the enzymes whose structures are presently known (21). The substrate binding site in such enzymes is
invariably formed by the loops which connect the β sheet and α helical segments that are located at the C-terminal end of the 8-stranded barrel. It seems probable that this region of the YKL-39 structure also has specific binding properties, forming either an active site or a specific glycan binding site.

We speculate that the high level of sequence identity between chitinases and YKL-39 in the region of the sequence that corresponds to the putative chitinase active site (Fig. 6, shaded residues) is best explained by the need to conserve residues involved in glycan binding and that YKL-39 is likely to bind a given glycan structure with high specificity. This hypothesis is supported by the fact that YKL-40 binds a glycan, heparin, with an affinity greater than found for the well established heparin binding of fibronectin (11). Since YKL-39 clearly has no affinity for heparin in spite of its similarity in net charge and sequence to YKL-40, it seems likely that heparin binding is attributable to a specific binding site on YKL-40, one that is conserved in all species tested (cow, human, pig). We are currently investigating the glycan binding specificities of YKL-39.

Physiologic Processes in Which YKL-39 Could Function—We think that the expression of YKL-39 at high levels in primary chondrocyte cultures suggests that the protein could function in tissue remodeling processes. Evidence for this hypothesis is provided by the identity of the other major proteins in chondrocyte-conditioned medium (Fig. 1). The most abundant protein in chondrocyte-conditioned medium, YKL-40, is thought to be involved in remodeling of breast tissue (7), vascular smooth muscle (11), and cartilage (4). YKL-40 is not in fact even expressed at detectable levels in normal cartilage or in cartilage explants until 2 days in culture (4) (data not shown). YKL-40 is, however, expressed at high levels in arthritic cartilage, an abnormal tissue characterized by high levels of tissue destruction and turnover. The next most abundant protein in chondrocyte-conditioned medium, prostromelysin, is an enzyme with broad substrate specificity which is involved with the digestion of a wide variety of extracellular matrix proteins in tissue remodeling processes. If YKL-39 is involved in the remodeling of cartilage, it is likely that YKL-39 is, like YKL-40, not expressed by normal cartilage but is induced in explant culture and expressed at high levels in arthritic cartilage.

REFERENCES
1. Henrissat, B., and Bairoch, A. (1993) Biochem. J. 293, 781–788
2. Coulson, A. F. W. (1994) FEBS Lett. 354, 41–44
3. Bost, R. G., Renkema, G. H., Strijland, A., van Zonneveld, A. J., and Aerts, J. M. F. G. (1995) J. Biol. Chem. 270, 26252–26256
4. Hakala, B. E., White, C., and Recklies, A. D. (1993) J. Biol. Chem. 268, 25803–25810
5. Johansen, J. S., Cintin, C., Jørgensen, M., Kamby, C., and Price, P. A. (1995) Eur. J. Cancer 31, 1437–1442
6. Arias, E. B., Verhage, H. G., and Jaffe, R. C. (1994) Biol. Reprod. 51, 685–694
7. Rejman, J. J., and Hurley, W. L. (1988) Biochem. Biophys. Res. Commun. 150, 329–334
8. Nyirkos, P., and Golds, E. E. (1990) Biochem. J. 268, 265–268
9. Johansen, J. S., Jørgensen, M., Rice, J. S., and Price, P. A. (1992) J. Bone Miner. Res., 7, 909–915
10. Johansen, J. S., Williamson, M. K., Rice, J. S., and Price, P. A. (1993) Br. J. Rheumatol. 32, 948–955
11. Shackleton, L. M., Marin, D. M., and Millis, A. J. T. (1995) J. Biol. Chem. 270, 13076–13083
12. Morrison, B. W., and Leder, P. (1994) Oncogene 9, 3417–3426
13. Maier, R., Ganu, V., and Lotz, M. (1993) J. Biol. Chem. 268, 21527–21532
14. Renkema, G. H., Bost, R. G., Mulijters, A. O., Donker-Koopman, W. E., and Aerts, J. M. F. G. (1995) J. Biol. Chem. 270, 2198–2202
15. Pearson, W. R., and Lipman, D. J. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 2444–2448
16. Kozak, M. (1989) J. Cell Biol. 108, 229–241
17. Von Heijne, G. (1983) Eur. J. Biochem. 133, 17–21
18. Watanabe, T., Oyanagi, W., Suzuki, K., Ohnishi, K., and Tanaka, H. (1992) J. Bacteriol. 174, 408–414
19. Myashita, K., and Fujii, T. (1993) Biosci. Biotechnol. Biochem. 57, 1691–1698
20. Watanabe, T., Kobori, K., Miyashita, K., Fuji, T., Sakai, H., Uchida, M., and Tanaka, H. (1993) J. Biol. Chem. 268, 18567–18572
21. Farber, G. K. (1993) Curr. Opin. Struct. Biol. 3, 409–412